Characteristics and Prognostic Implications of Peripheral Blood Lymphocyte Subsets in Patients with Anti-MDA5 Antibody Positive Dermatomyositis-interstitial Lung Disease

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2023 Oct 29

PMID 37898737

Authors

Fang-Ping Ren

Qi Chen

Shan-Shan Yao

Lin Feng

Xin-Ying Xue

Wei-Chao Zhao

Dong Wang

Zhi-Ling Zhao

Si-Wei Gu

Ting Li

Ya-Wen Shen

Lan Gao

Xue-Lei Zang

Xin-Yu Bao

Zhao-Hui Tong

Affiliations

Soon will be listed here.

Abstract

Objectives: To examine the characteristics of blood lymphocyte subsets in dermatomyositis-interstitial lung disease (DM-ILD) inflicted patients with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5), as well as its prognosis value in this set of patients.

Methods: Data were retrospectively collected from 253 DM-ILD patients from three hospitals in China between January 2016 to January 2021. Patients were grouped into anti-MDA5 antibody positive group (MDA5 DM-ILD) and anti-MDA5 antibody negative group (MDA5 DM-ILD) based on myositis-specific autoantibody test results. Demographic characteristics, lymphocyte subsets patterns and other clinical features were compared between the two groups. The association of lymphocyte subsets with 180-day mortality was investigated using survival analysis in MDA5 DM-ILD.

Results: Out of 253 eligible patients with DM-ILD, 59 patients were anti-MDA5 and 194 were anti-MDA5. Peripheral blood lymphocyte count, CD3 count, percentage of CD3, CD3CD4 count, and CD3CD8 count was lower in MDA5 DM-ILD than in MDA5 DM-ILD (all P < 0.001) as well as CD3CD19 count (P = 0.04). In MDA5 DM-ILD, CD3CD8 count ≤ 49.22 cell/μL (HR = 3.81, 95%CI [1.20,12.14]) and CD3-CD19 count ≤ 137.64 cell/μL (HR = 3.43, 95%CI [1.15,10.24]) were independent predictors of mortality. CD3CD8 count ≤ 31.38 cell/μL was associated with a higher mortality risk in all DM-ILD patients (HR = 8.6, 95%CI [2.12,31.44]) after adjusting for anti-MDA5 and other clinical characteristics.

Conclusion: Significant lymphocytes decrease was observed in MDA5 DM-ILD patients. CD3CD8 cell count was associated with worse prognosis in both MDA5 DM-ILD and all DM-ILD patients.

Citing Articles

An update on autoantibodies in the idiopathic inflammatory myopathies.

Allameen N, Ramos-Lisbona A, Wedderburn L, Lundberg I, Isenberg D Nat Rev Rheumatol. 2024; 21(1):46-62.

PMID: 39609638 DOI: 10.1038/s41584-024-01188-4.

Dysregulated CD38 expression on T cells was associated with rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 positive dermatomyositis.

Guo Y, Liu H, Chen B, Zhang K, Meng L, Yan L Front Immunol. 2024; 15:1455944.

PMID: 39588376 PMC: 11586385. DOI: 10.3389/fimmu.2024.1455944.

Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease.

Niu Y, Liu S, Qiu Q, Fu D, Xiao Y, Liang L Arthritis Res Ther. 2024; 26(1):184.

PMID: 39468670 PMC: 11520069. DOI: 10.1186/s13075-024-03415-5.

Dynamic change of lymphocytes associated with short-term prognosis in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multicenter retrospective study.

Tian Y, He P, Ren L, Xin H, Xi B, Zou R Clin Rheumatol. 2024; 43(11):3399-3408.

PMID: 39292419 PMC: 11489275. DOI: 10.1007/s10067-024-07110-3.

Peripheral Blood Lymphocyte Subsets and Heterogeneity of B Cell Subsets in Patients of Idiopathic Inflammatory Myositis with Different Myositis-specific Autoantibodies.

Pan Z, Li M, Zhang P, Li T, Liu R, Liu J Inflammation. 2024; 48(1):118-132.

PMID: 38755405 DOI: 10.1007/s10753-024-02052-z.

References

Galindo-Feria A, Albrecht I, Fernandes-Cerqueira C, Notarnicola A, James E, Herrath J . Proinflammatory Histidyl-Transfer RNA Synthetase-Specific CD4+ T Cells in the Blood and Lungs of Patients With Idiopathic Inflammatory Myopathies. Arthritis Rheumatol. 2019; 72(1):179-191. DOI: 10.1002/art.41075. View

Chawla A, Kumar T, Mukherjee P . Antisynthetase syndrome: Initial and follow-up imaging features. Lung India. 2018; 35(6):523-525. PMC: 6219130. DOI: 10.4103/lungindia.lungindia_4_18. View

Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R . Splicing variant of augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018; 77(4):602-611. DOI: 10.1136/annrheumdis-2017-212149. View

Dzangue-Tchoupou G, Allenbach Y, Preusse C, Stenzel W, Benveniste O . Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome. J Neuroimmunol. 2019; 332:212-215. DOI: 10.1016/j.jneuroim.2019.04.014. View

Zhang H, Yue J, Hou X, Lu H, Bikdeli A, Guo H . Rapidly progressive interstitial lung disease combined with pneumocystis jiroveci pneumonia in a patient with single anti-TIF-1γ antibody positive dermatomyositis in the context of an underlying tumor. BMC Pulm Med. 2023; 23(1):248. PMC: 10326956. DOI: 10.1186/s12890-023-02542-0. View

Li W, Tian X, Lu X, Peng Q, Shu X, Yang H . Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. Sci Rep. 2016; 6:27479. PMC: 4895339. DOI: 10.1038/srep27479. View

Alenzi F . Myositis Specific Autoantibodies: A Clinical Perspective. Open Access Rheumatol. 2020; 12:9-14. PMC: 6969688. DOI: 10.2147/OARRR.S231195. View

Lian X, Zou J, Guo Q, Chen S, Lu L, Wang R . Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model. Chest. 2020; 158(4):1535-1545. DOI: 10.1016/j.chest.2020.04.057. View

Temmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T . Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis. Medicine (Baltimore). 2019; 98(20):e15578. PMC: 6531063. DOI: 10.1097/MD.0000000000015578. View

10.

Pawlitzki M, Nelke C, Rolfes L, Hasseli R, Tomaras S, Feist E . NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells. 2021; 10(10). PMC: 8534165. DOI: 10.3390/cells10102551. View

11.

Wen L, Chen X, Cheng Q, Nie L, Xu J, Yan T . Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China. Clin Rheumatol. 2022; 41(11):3419-3427. DOI: 10.1007/s10067-022-06291-z. View

12.

Feng M, Guo H, Zhang C, Wang Y, Liang Z, Zhao X . Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int Immunopharmacol. 2019; 77:105912. DOI: 10.1016/j.intimp.2019.105912. View

13.

Mao M, Xia S, Guo B, Qian W, Zheng Z, Peng X . Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD. Respir Med. 2020; 172:105983. DOI: 10.1016/j.rmed.2020.105983. View

14.

Selva-OCallaghan A, Romero-Bueno F, Trallero-Araguas E, Gil-Vila A, Ruiz-Rodriguez J, Sanchez-Pernaute O . Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease. Curr Treatm Opt Rheumatol. 2021; 7(4):319-333. PMC: 8476986. DOI: 10.1007/s40674-021-00186-x. View

15.

DeWane M, Waldman R, Lu J . Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2019; 82(2):267-281. DOI: 10.1016/j.jaad.2019.06.1309. View

16.

Motegi S, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M . Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol. 2019; 29(5):511-517. DOI: 10.1684/ejd.2019.3634. View

17.

Ceribelli A, De Santis M, Isailovic N, Gershwin M, Selmi C . The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review. Clin Rev Allergy Immunol. 2016; 52(1):58-70. DOI: 10.1007/s12016-016-8527-x. View

18.

Sontheimer R . Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol. 1999; 11(6):475-82. View

19.

Chen F, Wang D, Shu X, Nakashima R, Wang G . Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2011; 32(12):3909-15. DOI: 10.1007/s00296-011-2323-y. View

20.

Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A . MDA5 Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN-κ Transcript. J Invest Dermatol. 2020; 140(6):1276-1279.e7. DOI: 10.1016/j.jid.2019.10.020. View